Articles tagged with Colon Cancer
Early-onset gastrointestinal cancers are rising globally, particularly among younger adults. Colorectal cancer is the most common early-onset GI cancer, accounting for over half of cases, and its incidence is increasing faster than any other type of early-onset cancer.
A 1,000-patient clinical study will use RNA-based stool and saliva tests to detect colon polyps, enabling early prevention of colorectal cancer. The study aims to develop an at-home RNA test that empowers people to take action before cancer takes hold.
The study highlights a significant increase in early-onset colorectal cancer rates globally, particularly in high-income countries. Younger patients are more likely to receive aggressive treatment without survival advantage, and survivors often report problems with anxiety, body image, and sexual dysfunction.
Researchers found that combining selinexor with Irinotecan shrunk tumors in preclinical models of colorectal cancer, suggesting a new potential treatment. The study also identified XPO1 mutations linked to rare cancers like endometrial cancer and found that these mutations make cells resistant to chemotherapy.
A study published in Radiology found that CT colonography is more effective and cost-effective than stool DNA testing for colorectal cancer screening, reducing incidence by 70-75% compared to 59%. CT colonography is also a cost-saving option with an estimated cost of $9,000 per QALY gained.
A study found significant gaps in testing for genetic cancer risk among patients with womb cancer, with less than half eligible receiving a blood test for Lynch syndrome. This can lead to delayed diagnosis and increased cancer risk, affecting not only the individual but also their family members.
A study found slightly lower adenoma detection rates in adults aged 45-49 compared to older groups, consistent with previous evaluations of screening colonoscopies. The study's findings suggest that the lowered screening age may have a beneficial effect on colon cancer prevention.
A phase 3 trial of patients with surgically resected stage 3 dMMR colon cancer found that adding an immune checkpoint inhibitor (atezolizumab) to standard chemotherapy improved disease-free survival by 50% compared to chemotherapy alone. The study results provide new evidence for a treatment approach in this high-risk patient population.
Charité researchers identified a therapeutic target that significantly contributes to halting ongoing inflammatory processes. They found that interleukin-22 and oncostatin M drive inflammation by amplifying the immune response. Targeted treatments may help high-risk patients, but chronic diseases remain complex and difficult to predict.
A new study found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer resulted in a 50% reduction in cancer recurrence and death compared to chemotherapy alone. The treatment combination showed significant benefits for patients with deficient DNA mismatch repair genetic makeup.
The ATOMIC trial demonstrates a statistically significant improvement in disease-free survival with the addition of atezolizumab to standard adjuvant FOLFOX chemotherapy. Patients treated with atezolizumab had a 50% lower risk of disease recurrence or death compared to those receiving chemotherapy alone.
A Dana-Farber study found that patients with stage III colon cancer who consumed an anti-inflammatory diet had longer overall survival post-treatment compared to those on a proinflammatory diet. Engaging in higher levels of physical activity also amplified the positive influence on survival.
Researchers from Mayo Clinic Comprehensive Cancer Center will present practice-changing studies on chemotherapy approaches, AI applications in oncology, and new therapies for breast and melanoma. The event will feature 59 abstracts highlighting advancements in cancer care.
A study published in PNAS reveals that colorectal cancer cells utilize a protein called TBX3, which regulates embryo development, to contribute to their aggressiveness and metastasis. The discovery opens up possibilities for developing targeted therapies to prevent tumor cell spread.
Researchers from City of Hope will present novel cancer treatment approaches and combinations, including innovative combination therapies for breast, genitourinary, and gastrointestinal cancers. Additionally, they'll discuss the safety of readministering trastuzumab-deruxtecan to metastatic breast cancer patients with low-grade lung co...
Researchers at UCSF found that certain gut bacteria can reduce chemotherapy side effects by clearing excess drugs and producing the protective vitamin K2. Patients with more beneficial bacteria had fewer side effects, suggesting that probiotics may help mitigate chemotherapy's impact.
Researchers at The University of Osaka found that localized oxygen deficiency in colon tumors can promote tumor growth by transforming normal fibroblasts into inflammatory fibroblasts. These altered cells release factors that help tumors grow, offering a potential new target for cancer therapy.
Researchers found AI outperformed physicians in answering GI cancer questions, with oncologists preferring ChatGPT's responses nearly 80% of the time. Additionally, fewer patients are getting surgery for benign colon polyps as endoscopic techniques rise, reducing serious complications and mortality rates.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Flinders University researchers found that most people, regardless of age, want more frequent bowel cancer surveillance. A faecal test may provide reassurance for those at risk, particularly younger adults with a higher fear of bowel cancer.
Researchers at the University of California San Diego School of Medicine have found that high cannabis use is associated with increased mortality in colon cancer patients. The study analyzed data from over 1,000 patients and found a significant link between heavy cannabis use and reduced survival rates.
Researchers at Ohio State University have identified new targeted therapies for treating small cell lung cancer, predicting melanoma spread, and reducing endometrial cancer risk. A 31-gene expression profile has been developed to identify patients at high risk of melanoma spread, allowing for closer monitoring and earlier treatment.
A 20-year initiative that offered flexible screening options at a major health system doubled screening rates and cut cancer incidence by a third, halving deaths. The program eliminated racial disparities in outcomes, with Black patients' deaths declining from 52.2 to 23.5 per 100,000.
Hyperbaric oxygen treatment has been shown to provide long-term relief for patients with late radiation-induced injuries, improving symptoms of urinary incontinence, bleeding, and severe pain. The treatment can lead to the healing of chronic injuries and allow patients to live a fully normal life.
A UConn clinical trial confirms walnuts improve colonic health by reducing systemic inflammation and increasing the production of potent anti-inflammatory molecules called urolithins. Elevated urolithin A levels correlated with reduced colon cancer risk, particularly in obese patients.
Researchers analyzed CRC tumors with high tumor mutation burden to characterize BRAF-associated mutations and decipher their role in carcinogenesis. They found TMB-high tumors likely arise from a heterogeneous population of cells harboring numerous gene mutations distinct from driver oncogenes.
The study directly compared Droplet-based scRNA (D-scRNA) and Picowell-based scRNA (P-scRNA) platforms for analyzing human mucosal biopsies. D-scRNA provides more detailed insights, but requires resources and may introduce contamination. P-scRNA is gentler, more resource-efficient, but less effective in capturing rare cell types.
A new study suggests that CT scans could account for 5% of all cancer cases each year, primarily due to radiation exposure. The largest risk is among infants, followed by children and adolescents. To mitigate this risk, reducing the number of scans and doses per scan can help save lives.
A survey by the Annenberg Public Policy Center found that over half of Americans believe drinking alcohol increases their chances of developing cancer. The Surgeon General's advisory on alcohol and cancer risk also contributed to increased public awareness, with nearly 3 in 10 respondents saying they would be less likely to accept a dr...
A new study led by the University of Michigan Rogel Cancer Center found that patients with three specific variants face no extra risk of dying from their cancer. The researchers used data from the Surveillance, Epidemiology and End Results programs in Georgia and California, looking at a total of about 78,000 patients with breast, colo...
A new clinical guideline from the American Gastroenterological Association suggests that artificial intelligence-assisted colonoscopy may improve polyp detection rates, but its impact on preventing colorectal cancer remains uncertain. The guideline recommends a cautious approach to widespread adoption, emphasizing the need for further ...
Researchers at the University of Texas at El Paso have developed a portable, blood-based device that can detect colon cancer using a biomarker called CCSP-2. The device has the potential to provide early detection and treatment options for this second-deadliest US cancer, making it a significant advancement in colorectal cancer screening.
A study of nearly 2,500 postmenopausal women found that taking more daily steps and engaging in moderate-to-vigorous physical activity were associated with a significantly reduced risk of death from cardiovascular disease. Even walking fewer than 5,000 steps per day showed a risk reduction.
The updated recommendations from the US Multi-Society Task Force on Colorectal Cancer aim to achieve a benchmark of 90% exams with adequate bowel preparation. The guidelines focus on optimizing bowel preparation before, during, and after colonoscopy, including patient education, dietary restrictions, and choice of preparation agent.
A recent study published in CANCER suggests that higher levels of physical activity may lessen and even eliminate survival disparities among colon cancer survivors. Cancer survivors who regularly exercised achieved better subsequent survival rates than those seen in the matched general population, with a 3.1% lower risk at year three.
Deep Nanometry enables high-speed analysis of nanoparticles, detecting even trace amounts of rare particles like extracellular vesicles indicative of colon cancer. This technique has potential applications in various fields including vaccine development and environmental monitoring.
Researchers discover that the gene HMGA1 'opens' regions of the genome to activate stem cell genes, leading to tumor development and progression. High levels of HMGA1 also allow mutant tumor cells to escape detection by immune cells.
Researchers at UCSF have identified unique, cancer-specific proteins created through mistakes in RNA splicing. These antigens could be used to create potent immunotherapies that recognize and attack hard-to-treat tumors. The discovery offers new hope for glioma patients and expands the number of targets available for cancer therapy.
The Micro Immune Response On chip (MIRO) replicates tumours and their environment, allowing researchers to study the efficacy of immunotherapy treatments. This technology has been tested with breast cancer samples and shows promise in understanding how the immune system interacts with tumours.
A blood test using Signatera detected tiny fragments of tumor DNA in the blood, which showed that adding celecoxib to treatment may improve disease-free survival for patients with stage III colon cancer. The analysis found significantly improved outcomes for those taking celecoxib compared to placebo.
A blood test detecting circulating tumor DNA (ctDNA) can predict stage 3 colon cancer patients' risk of recurrence. Adding anti-inflammatory drug celecoxib to post-surgery treatment improves disease-free survival for those with positive ctDNA tests.
A review of 3,000 studies suggests microplastics in the air may cause serious health problems, including colon cancer, poor lung function, and infertility. The tiny plastic particles are believed to contribute to chronic pulmonary inflammation, increasing the risk of lung cancer.
Researchers at UW-Madison found two microbial bile acids that affect colon cancer risk in opposite ways, with one slowing growth and the other fueling tumors. The study provides a roadmap for new cancer detection methods and treatments.
A new study suggests that a person's biological age can predict their risk of developing colon polyps and early colorectal cancer. Accelerated aging, which is higher than chronological age, may be linked to a greater risk of developing the disease, highlighting the importance of early screening.
A study led by UF Health Cancer Center researchers found that a toxin in the bacteria Campylobacter jejuni accelerates the spread of colorectal tumors. The findings could lead to new tools for detecting metastatic colorectal cancer early, ultimately helping determine patients who need more aggressive treatments.
The American College of Surgeons' annual cancer report reveals that breast, bladder, and pancreatic cancers are increasingly treated with personalized therapies before surgery. Cancer stage at diagnosis remains a significant factor in determining patient survival rates.
Researchers at POSTECH have identified GLUT3 as essential for the suppressive function of regulatory T cells in tumor microenvironments, which can be targeted for cancer immunotherapy. The team's findings highlight the critical role of GLUT3 in regulating protein modifications that sustain immune suppression within tumors.
Scientists are investigating whether resveratrol, a compound found in red grapes, can prevent bowel cancer. The COLO-PREVENT trial is testing multiple potential prevention drugs, including aspirin and metformin, to see if they can slow down tumour growth and reduce the risk of bowel cancer.
Researchers found higher levels of CD47 expression linked to more aggressive tumors, immune cells, and oncogenic signaling. Targeting CD47 could lead to improved outcomes with immunotherapy drugs, especially in cases where existing treatments are ineffective.
Researchers have found that specific E. coli bacteria in the gut promote colon cancer by binding to intestinal cells and releasing a DNA-damaging toxin called colibactin. This binding is made possible by bacterial pili and adhesins, which can be targeted to prevent tumor development.
Researchers at Tel Aviv University have discovered a new cancer mechanism that prevents the immune system from attacking tumors. The discovery was made by reversing this mechanism, which stimulates the immune system to fight cancer cells, including those resistant to prevailing forms of immunotherapy.
Researchers create genetic barcoding approach to record cellular events and clonality in vivo, revealing that colorectal cancer originates from multiple healthy cells. This work provides a new understanding of the transition from polyclonal to monoclonal composition in advanced stages.
Researchers found a link between non-functional p53 genes and the regenerative cell state in ulcerative colitis, leading to cancer progression. A new diagnostic test could identify aberrant cells earlier using molecular tools.
A Kaiser Permanente study found that close to 39% of adults aged 45-49 returned their FIT kit, compared to nearly 38% of adults aged 50. The study suggests that adults in this age group have a similar colorectal cancer risk as those aged 50.
Younger adults diagnosed with colorectal cancer have later-stage disease with more aggressive types of tumors. Obesity, family history, inflammatory bowel disease, and symptoms are strongly associated factors. These findings highlight disparities in colon cancer incidence among younger adults, particularly non-Hispanic Black patients.
A new study found that 5-fluorouracil kills cells by interfering with RNA synthesis, not DNA damage. The findings suggest that combining 5-FU with drugs affecting RNA synthesis could make it more effective in patients with gastrointestinal cancers.
Scientists at RIKEN CPR created a method to change albumin's molecular ID card, allowing for targeted treatments against diseases like cancer. The new technology can transport proteins out of the body, mimicking drug delivery and removal.
A new study aims to increase follow-up care for patients who receive abnormal stool-based fecal immunochemical tests, focusing on improving coordination between primary and specialty clinics. The goal is to improve colorectal cancer screening processes in underserved populations, increasing survival and reducing mortality.
The Affordable Care Act has led to increased guideline-concordant care for non-white patients, rural residents, and those from the most deprived neighborhoods in Pennsylvania. This improvement is associated with better cancer outcomes, including survival rates.
Researchers have discovered a new class of natural antimicrobials called microcins that can target specific strains of bacteria causing cholera, inflammatory bowel disease, and colon cancer. Microcins are highly selective and can potentially remove unwanted bacteria without disrupting the human gut microbiome.